v3.26.1
Stockholders' equity - Summary of Company's Outstanding Warrants Exercisable for Shares of Common Stock (Details)
Jun. 30, 2026
$ / shares
shares
September 2023 Pre-Funded Warrants [Member]  
Equity classified warrants  
Number of warrants (in Shares) | shares 338,252
Exercise price | $ / shares $ 0.0001
February 2025 Common Warrants [Member]  
Equity classified warrants  
Number of warrants (in Shares) | shares 4,418,292 [1]
Exercise price | $ / shares $ 3.395 [1]
February 2025 Pre-Funded Warrants [Member]  
Equity classified warrants  
Number of warrants (in Shares) | shares 657,708
Exercise price | $ / shares $ 0.0001
[1] The February 2025 common warrants will expire on the earlier of: (i) the 60th day after the date the FDA approves the NDA for GTx-104 or (ii) September 25, 2028.